TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06668727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepB mAb19
Description: The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD.
Study: NCT04230499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Rapamycin (eRapa)
Description: eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Rapamycin (eRapa)
Description: eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Rapamycin (eRapa)
Description: eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Rapamycin (eRapa)
Description: eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
Study: NCT05272787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer B (Control)
Description: All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Auxiliary product
Study: NCT05964855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Variable Stiffness Prosthesis
Description: Proprietary electronically-controlled prosthesis that can vary its effective stiffness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Variable Equilibrium Angle Prosthesis
Description: Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIT Sliding Beam Passive Prosthesis
Description: Proprietary fixed-stiffness passive foot-ankle prosthesis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Pro-flex XC
Description: Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blatchford Elan Variable-Dampening Prosthesis
Description: Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
Study: NCT05272787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Auxiliary product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial wash
Description: Auxiliary product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial wash
Description: Auxiliary product.
Study: NCT06230614

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colistin 1 MU in normal saline 1 ml
Description: Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colistin 1 MU in normal saline 2 ml
Description: Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml
Study: NCT06481254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hawthorn Vinegar Group
Description: To routine oral mucositis treatment, patients with DM in the hawthorn vinegar group gargled with 1 tablespoon (10 cc) of diluted hawthorn vinegar (mixed with 40 cc water) for 1 minute 15-20 minutes before meals 3 times a day for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Mulberry Syrup Group
Description: To routine oral mucositis treatment, patients with DM in the black mulberry syrup group pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea Group
Description: To routine oral mucositis treatment, patients with DM in the green tea group gargled with 50 cc green tea for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
Study: NCT04912674

Intervention type: DEVICE
Intervention: Symphony OCT System
Description: Surgical intervention will be patient specified by treating surgeon.
Study: NCT06564636

Intervention type: DEVICE
Intervention: CATALYSTEM
Description: CATALYSTEM Cementless Primary Hip System for participants with Total Hip Arthroplasty
Study: NCT04222335

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes.
Study: NCT04380038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab Injectable Product
Description: Nasal inoculation, single dose 300 TCID50 in 1ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab Injectable Product
Description: Nasal inoculation, single dose 300 TCID50 in 1ml.
Study: NCT04231266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ManNAc
Description: Oral N-acetyl-D-mannosamine monohydrate (ManNAc)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05087329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Mindfulness Meditation
Description: Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
Study: NCT05330325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
Study: NCT06645652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in observational drawing
Description: * 6 weeks of online gallery browsing based on different topics~* Daily practice drawing from observation with training adding up to 1 hour a week~* Documenting progress and reflection writing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arts engagement through digital galleries
Description: * 6 weeks of online gallery browsing based on different topics~* 2 hours of weekly activities consist of reading and navigating technology~* Reflection writing
Study: NCT05529758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internalized Weight Bias Intervention
Description: ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, \& Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, \& Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
Study: NCT06646471

Intervention type: GENETIC
Group type: OTHER
Intervention: Bio-bank repository
Description: Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life (QoL)
Description: Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:~* stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.~* operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.~* radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: G-Code
Description: G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
Study: NCT06344104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered orally, once daily (QD).
Study: NCT05744557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: num Vapocoolant
Description: Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
Study: NCT05105425

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NUTRIOSE®
Description: After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: GLUCIDEX® IT21 (Placebo)
Description: After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).
Study: NCT05363098

Intervention type: OTHER
Intervention: Mechanically ventilated neurosurgical patients
Description: Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
Study: NCT06666023

Intervention type: DEVICE
Intervention: Device
Description: Use of the device in groups to test its ability to diagnose infections.

Intervention type: DEVICE
Intervention: Device
Description: Use of the device in groups to test its ability to diagnose infections.
Study: NCT06668389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (Dapagliflozin 10mg)
Description: Subjects in SGLT2 inhibitor Group will take dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)
Study: NCT06668792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-248
Description: subcutaneously
Study: NCT06664099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)
Description: This intervention involves performing a One Anastomosis Gastric Bypass surgery with the bypassed length of the small intestine set at 150 centimeters from the duodenojejunal junction. This shorter limb length is designed to achieve weight loss while potentially reducing the risk of nutritional deficiencies. The procedure is performed laparoscopically, with the stomach divided to create a gastric tube attached to a loop of the small intestine. Postoperative outcomes will include assessments of weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers such as albumin, calcium, and iron.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)
Description: This intervention involves performing a One Anastomosis Gastric Bypass surgery with a bypassed length of 170 centimeters from the duodenojejunal junction, offering an intermediate limb length. This distance is intended to balance weight loss effectiveness with moderate risks of nutritional deficiencies. The laparoscopic procedure involves creating a gastric tube attached to a segment of the small intestine, bypassing the proximal portion. Outcomes monitored postoperatively include weight loss, percentage of total and excess weight loss, and nutritional parameters such as albumin, calcium, and iron levels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)
Description: This intervention consists of performing a One Anastomosis Gastric Bypass with the bypass length set at 200 centimeters from the duodenojejunal junction. This longer bypass length is designed to maximize weight loss outcomes but may carry a higher risk of nutritional deficiencies. The procedure is done laparoscopically, where the stomach is divided, creating a tube that is joined to the small intestine at the specified length. Postoperative assessments will focus on weight loss effectiveness, total and excess weight loss percentages, and the risk of nutritional deficiencies by measuring markers such as albumin, calcium, and iron.
Study: NCT06594133

Intervention type: DRUG
Intervention: Antibiotic Treatment
Description: For lung transplant recipients with Nocardia infection, the treatment regimen could include:~Sulfamethoxazole/Trimethoprim (Bactrim): 800 mg/160 mg orally or intravenously twice daily for at least 6 months.~Imipenem: 500 mg intravenously every 6 hours for severe cases. Monitoring: Regular monitoring of blood levels of the drug to avoid toxicity and adjust doses accordingly.
Study: NCT05455320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or intravenously.
Study: NCT05477407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
Description: Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
Study: NCT06665282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed high intensity laser therapy
Description: The study employs a BTL-6000 high-intensity laser therapy (12 W) to apply high intensity laser therapy to deep tissues. high intensity laser therapy therapy uses powerful beams (\>500 mw) to penetrate deeper, delivering high multi-directional energy in a short time. Pulsed laser therapy, a form of high intensity laser therapy therapy, enhances cell metabolism without disrupting it.~High-intensity laser therapy is a safe treatment method consisting of three phases. The first phase involves fast scanning around the wrist, hand, and fingers, with fluencies set at 510, 610, and 710mJ/cm2. The second phase involves holding the handpiece vertically to 90° on 10 fixed points around the metacarpophalangeal and interphalangeal joints, each radiated for 15 seconds, and a total dose of 1500 J. The third phase is the same but at a slower rate, with a total energy of 300 J.
Study: NCT05549258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Inebilizumab administered intravenously (IV) over a total of 28 weeks.
Study: NCT05220098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-280
Description: Participants will receive TAK-280 as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-280
Description: Participants will receive TAK-280 as IV infusion.
Study: NCT04603898

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbon-13 Ascorbic Acid Oral Load
Description: Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
Study: NCT04024917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac coherence
Description: An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~- The program cardiac coherence will be performed during 90 days after the surgery
Study: NCT06665282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham pulsed high intensity laser therapy
Description: Patients in the control group will receive sham high-intensity laser therapy, where all parameters will be set up without switching on the start button and high intensity laser therapy machine is switched on with a visible light beam only
Study: NCT04024917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study: NCT06665282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy program
Description: All patients of the study and control groups will receive the same routine physical therapy program for 30minutes and three times per week for successive eight weeks in the form of hot therapy, stretching and strengthening exercises. Hot therapy, in the form of warm baths for 10minutes, is applied before stretching exercises on the wrist joint and fingers to relieve joint pain and increase the range of motion. Strengthening exercises are in the form of isometric exercise for hand muscles and fingers to maintain muscles strength and joints flexibility
Study: NCT00733694

Intervention type: DEVICE
Group type: OTHER
Intervention: LCS® Complete™ Mobile Bearing Knee Systems
Description: An orthopaedic implant for primary total knee replacement with a mobile bearing knee
Study: NCT06665282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy program
Description: All patients of the study and control groups will receive the same routine physical therapy program for 30minutes and three times per week for successive eight weeks in the form of hot therapy, stretching and strengthening exercises. Hot therapy, in the form of warm baths for 10minutes, is applied before stretching exercises on the wrist joint and fingers to relieve joint pain and increase the range of motion. Strengthening exercises are in the form of isometric exercise for hand muscles and fingers to maintain muscles strength and joints flexibility
Study: NCT06667349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
Study: NCT06668688

Intervention type: DEVICE
Intervention: ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de)
Description: The web-based information platform for educational professionals ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. The website is intended to provide low-threshold information about depression and mental health in the school context.
Study: NCT05498428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.